Company Analysis

Impact BioMedical, Inc. (IBO)

NYSE: IBO · Pharmaceutical Preparations · Houston, TX · filing with the SEC since 2021
Grade5.0
◀ Past 7.4● Present 4.0▶ Future 4.3
5 est.

Filings

117 filings since 2017 beside 39 insider forms · Non-accelerated filer and smaller reporting company and emerging growth company · read from EDGAR on Nov 13, 2026
Due nextNon-accelerated filer and smaller reporting company and emerging growth company
10-K Annual report for the fiscal year ending Dec 31, 2026Non-accelerated filers and smaller reporting companies have 90 days after the fiscal year ends. by Mar 31, 2027
10-Q Quarterly report for the quarter ending Mar 31, 2027Non-accelerated filers and smaller reporting companies have 45 days after the quarter ends; quarter ends are taken to the month end. by May 15, 2027

A deadline is the latest date the SEC's rules allow for its filer category. It is not a forecast of the day the company files. The proxy statement was last filed Sep 22, 2025.

Filings a yearinsider forms included
51229483329
202120222023202420252026

2026 counts to Nov 13, 2026.

Officer or director change (8-K item 5.02): 3 times in the last 36 months, the newest Mar 13, 2025.SEC letters: 15 in the last 36 months, the newest Mar 10, 2025.
Insider forms 39

Insider forms (3, 4, 5 and 144) are counted each year but not listed here; the people and their trades are on the Ownership tab.

FiledFormWhat it is, in plain wordsPeriodAsk
Nov 9, 2026 10-Q Quarterly report Sep 30, 2026
Nov 3, 2026 8-K items 7.01, 9.01 Investor disclosure (Regulation FD) · Current report Nov 2, 2026
Nov 3, 2026 425 Merger communication
Oct 27, 2026 DEFM14A Merger proxy statement
Oct 9, 2026 8-K items 5.03, 9.01 Charter, bylaw or fiscal-year change · Current report Sep 23, 2026
Sep 17, 2026 425 Merger communication
Sep 17, 2026 8-K items 7.01, 9.01 Investor disclosure (Regulation FD) · Current report Sep 16, 2026
Sep 15, 2026 425 Merger communication
Sep 15, 2026 8-K items 7.01, 9.01 Investor disclosure (Regulation FD) · Current report Sep 14, 2026
Aug 7, 2026 10-Q Quarterly report Jun 30, 2026
May 12, 2026 10-Q Quarterly report Mar 31, 2026
Apr 22, 2026 S-8 POS Employee stock plan update
Apr 6, 2026 S-8 POS Employee stock plan update
Mar 11, 2026 10-K Annual report Dec 31, 2025
Mar 4, 2026 8-K items 1.01, 9.01 Major agreement signed · Current report Feb 27, 2026
Dec 30, 2025 DEF 14C Information statement
Dec 11, 2025 PRE 14C Preliminary information statement
Nov 7, 2025 10-Q Quarterly report Sep 30, 2025
Nov 6, 2025 8-K item 5.07 Shareholder vote · Current report Nov 5, 2025
Oct 27, 2025 8-K item 8.01 Other event · Current report Oct 24, 2025
Sep 22, 2025 DEF 14A Proxy statement
Sep 9, 2025 DEF 14C Information statement
Aug 25, 2025 PRE 14C Preliminary information statement
Aug 14, 2025 10-Q Quarterly report Jun 30, 2025
Aug 5, 2025 DEF 14C Information statement
Jul 28, 2025 8-K items 1.01, 9.01 Major agreement signed · Current report Jul 21, 2025
Jul 16, 2025 PRE 14C Preliminary information statement
Jun 23, 2025 8-K items 1.01, 7.01, 9.01 Major agreement signed; Investor disclosure (Regulation FD) · Current report
May 14, 2025 10-Q Quarterly report Mar 31, 2025
Apr 4, 2025 SCHEDULE 13D/A Activist holder update, amended
Apr 3, 2025 8-K item 1.01 Major agreement signed · Current report
Apr 2, 2025 SCHEDULE 13D Activist holder notice
Mar 28, 2025 10-K Annual report Dec 31, 2024
Mar 28, 2025 8-K items 1.01, 9.01 Major agreement signed · Current report Mar 24, 2025
Mar 13, 2025 8-K item 5.02 Officer or director change · Current report Mar 11, 2025
Mar 10, 2025 UPLOAD SEC comment letter
Mar 7, 2025 CORRESP Reply to the SEC
Feb 6, 2025 UPLOAD SEC comment letter
Jan 29, 2025 8-K items 7.01, 9.01 Investor disclosure (Regulation FD) · Current report
Jan 24, 2025 S-8 Employee stock plan registration
40 of 117 shown

Every row opens the filing on EDGAR. The plain words are the site's own for each form and each 8-K item; the complete history, insider forms included, is on EDGAR.

SI Assistanton IBO · research, not advice